VASOPRESSIN TANNATE - Generic Drug Details

What are the generic drug sources for vasopressin tannate and what is the scope of patent protection?

Vasopressin tannate is the generic ingredient in one branded drug marketed by Parke Davis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for VASOPRESSIN TANNATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	40
DailyMed Link:	VASOPRESSIN TANNATE at DailyMed

US Patents and Regulatory Information for VASOPRESSIN TANNATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	PITRESSIN TANNATE	vasopressin tannate	INJECTABLE;INJECTION	003402-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Vasopressin Tannate: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is vasopressin tannate’s market structure?

Vasopressin tannate is a long-acting, depot formulation of vasopressin created by complexing vasopressin with tannic acid. The market behaves like a specialty, low-volume, supply-constrained hormone product rather than a high-volume chronic drug, with demand concentrated in narrow indications and geographies.

Demand drivers

• Indication specificity: Use is tied to conditions where vasopressin is clinically appropriate (historically including bleeding control in select settings and endocrine-related use cases depending on jurisdiction and labeling).
• Depot kinetics: The “long-acting” profile affects substitution patterns. Where equivalent long-acting products exist, competition concentrates on dosing interval, availability, and local prescribing habits.
• Procurement and reimbursement: Hospital procurement cycles and reimbursed formularies typically govern uptake more than direct-to-consumer channels.

Supply-side dynamics

• Manufacturing complexity: Depot formulations and peptide stability requirements create higher barriers for entrants versus simple generics. This tends to limit the number of suppliers in a market.
• Quality and batch consistency: Small changes in formulation execution can change release and tolerability, so qualification and pharmacovigilance friction persists.
• Regulatory fragmentation: Different countries regulate vasopressin preparations under varied historical pathways, which shapes where products can be commercialized and for how long.

Who competes with vasopressin tannate?

Competition typically comes from:

• Other vasopressin formulations (short-acting aqueous vasopressin vs long-acting depot presentations).
• Therapeutic alternatives depending on the underlying clinical pathway (examples vary by indication and jurisdiction).
• Local legacy products with entrenched hospital use.

Because vasopressin tannate is formulation-specific, competitive pressure often shows up as therapeutic substitution within vasopressin class rather than as broad same-ingredient generic competition.

What is the pricing and reimbursement reality for this class?

Market pricing for vasopressin preparations generally tracks:

• Hospital channel economics (tenders, contracting, and emergency or episodic stock needs).
• Formulation status (long-acting depots often price above short-acting comparators but not on a blockbuster-like basis).
• Regulatory standing (whether supply is limited to one or two distributors in a territory).

In most geographies, vasopressin products price as specialty injectables: higher per unit than basic generics, but with constrained volume and limited ability to pass through raw cost inflation.

How has commercialization played out historically?

Vasopressin tannate is not typically a mass-market product. The historical pattern for this class is:

• Stable but modest demand in countries where a depot vasopressin presentation is established.
• Supply discontinuations and re-registrations that can cause short-term market gaps.
• Localized market presence where distribution networks and regulatory approvals support ongoing tender participation.

This creates a financial trajectory that is usually defined by:

• Cashflow stability driven by repeat hospital procurement,
• Volatility from supply events (batch disruptions, distributor changes, regulatory actions),
• Limited upside unless a territory adds new reimbursement or expands labeled use.

What is the financial trajectory profile?

For specialty depot hormone products like vasopressin tannate, the financial trajectory tends to follow a mature-specialty curve rather than a growth curve:

Typical lifecycle shape

• Early market formation: localized approvals and contracting establish baseline volume.
• Maturity: volume plateaus as prescribing stabilizes and procurement cycles normalize.
• Episodic step-changes: supply interruptions, tender renegotiations, and labeling updates drive stepwise revenue movements.
• Late lifecycle risk: as older products face regulatory renewal costs or manufacturing relocation, revenue can compress even without direct clinical obsolescence.

Revenue drivers

• Units per period: primarily tied to hospital stocking behaviors and case incidence for labeled use.
• Net price: tender-driven, compressed by supplier competition and contracting leverage.
• Cost of goods: depot peptide formulations face higher release testing, stability testing, and batch QA overhead.
• Working capital: injectable specialties often show tight-to-moderate inventory needs but can become stressed around supply constraints.

Which market events most impact revenue and margins?

The biggest levers for vasopressin tannate market performance are operational and regulatory rather than purely clinical.

Revenue-impacting events

• Regulatory status changes (approval renewals, label revisions, import authorization updates).
• Supply continuity (batch failures, line shutdowns, contract manufacturing shifts).
• Tender outcomes (switching to competitors, price renegotiation, or inclusion/exclusion on formularies).

Margin-impacting events

• QA and stability release costs: peptide depot products require strong batch release regimes.
• Repackaging and distribution: multi-tier distribution in hospital channels raises logistics margins pressure.
• Inventory write-down risk: where shelf-life constraints or market discontinuations occur, obsolete stock can hit earnings.

What does the competitive and regulatory landscape imply for investment returns?

Returns usually track three variables:

1. Sustained supply in the key geographies where it is stocked.
2. Retention of reimbursement/tender placement.
3. Protection from formulation substitution by other long-acting vasopressin offerings.

When these hold, the product often produces stable, low-growth cash generation. When any fail, financial performance can drop quickly due to the smaller base of customers and the higher cost of switching therapy in institutional procurement.

What is the likely trajectory under patent and exclusivity constraints?

Vasopressin itself is a legacy molecule. The value often concentrates in:

• Formulation-specific IP (vasopressin-tannin complex process and depot formulation details),
• Manufacturing know-how (release profile control and stability),
• Local regulatory dossiers and market authorizations.

Once formulation or process protections expire in a given jurisdiction, the market can shift toward:

• Lower priced authorized generics if regulatory pathways exist, or
• Reduced supply diversity if entry is too manufacturing-heavy.

The result is often a margin compression phase with limited volume rebound.

How should you model near-term market dynamics?

A practical model for vasopressin tannate should assume:

• Flat to low growth in volume, with growth only when a territory adds a reimbursement or formulary inclusion.
• Price pressure in tenders when multiple suppliers participate.
• Revenue volatility tied to supply continuity events.

Scenario logic

• Base case: stable procurement, moderate net price, controlled supply.
• Upside: expanded inclusion in additional hospital systems or territories and improved supply continuity.
• Downside: tender loss to an alternative vasopressin product or supply disruption leading to temporary revenue gaps.

What are the business implications for R&D and licensing?

If vasopressin tannate is evaluated for development, the economic thesis typically hinges on:

• Differentiated release profile versus existing depot vasopressin products.
• Manufacturing robustness to prevent batch failures and supply interruptions.
• Regulatory strategy that reduces time-to-market and supports faster dossier acceptance.

If entry is limited to formulation imitation, financial upside becomes constrained by tender-led pricing and the small base of institutional buyers.

Key data anchors used for this assessment

The analysis is grounded in how depot peptide/biologic injectables typically transact in hospital systems and how formulation-specific competitive substitution functions in narrow, specialty markets. While vasopressin itself is old, vasopressin tannate’s commercial behavior follows the formulation product lifecycle pattern rather than a classic blockbuster dynamic.

Key Takeaways

• Vasopressin tannate is a specialty, depot injectable with narrow demand concentration and hospital-tender-driven commercial dynamics.
• Market growth is usually limited; financial outcomes mainly depend on supply continuity, tender positioning, and reimbursement/formulary retention.
• Revenue tends to plateau after initial establishment, with stepwise volatility from regulatory or manufacturing events.
• Margin pressure is persistent if formulation-specific protections erode, because substitution within vasopressin long-acting options can shift pricing quickly in institutional contracting.
• Investment and licensing value typically concentrates in operational reliability and regulatory endurance, not clinical novelty.

---

FAQs

1) Is vasopressin tannate typically a high-growth product?

No. The commercial pattern is typically mature-specialty: modest volume, tender-governed pricing, and limited upside unless a territory adds or expands formulary inclusion.

2) What most often changes revenue the fastest?

Supply events (batch disruptions, manufacturing or distributor continuity), followed by tender outcomes and inclusion/exclusion on hospital formularies.

3) How does competition usually affect pricing?

Competition usually pressures net price during hospital contracting because purchasing is institutional and product substitution within vasopressin formulations is feasible.

4) What protects margins over time?

Sustained supply reliability, consistent batch quality and release performance, and protected market access via regulatory standing and retained contracting position.

5) Where does licensing value typically concentrate for formulation products like this?

On the ability to reliably manufacture the depot formulation and maintain market authorizations in key jurisdictions, since volume is limited and pricing is contract-driven.

---

References

[1] European Medicines Agency. (n.d.). Public assessment reports and product information for vasopressin-containing medicinal products. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. (n.d.). Drug approvals and labeling database for vasopressin and related formulations. https://www.accessdata.fda.gov/